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Background: We investigated whether the carriage of Blastocystis in IBS patients was associated with differences in
the faecal microbiota. Forty patients with diarrhoea-predominant IBS (26 Blastocystis-positive and 14 Blastocystis-
negative) and 57 healthy controls (HC) (42 Blastocystis-positive and 15 Blastocystis-negative) submitted faecal
samples for metataxonomic analysis of the 16S ribosomal RNA gene. Differences in the relative abundance of
bacteria in these IBS and HC groups were evaluated from phylum to genus level.
Results: Significant changes were observed in two dominant phyla in IBS patients, regardless of Blastocystis infection
status, namely a rise in Firmicutes and a statistically significant reduction in relative abundance of Bacteroidetes (with a
threefold increase in the Firmicutes to Bacteoridetes ratio). Significant differences at genus level in IBS subjects compared
to HC were also observed for many bacterial species. However, further clinical subgroup analysis of Blastocystis-positive
and Blastocystis-negative subjects, regardless of symptoms, showed no significant differences at the phylum or genus
level in IBS-P compared to IBS-N.
Conclusions: Significant differences in the faecal microbiota between diarrhoea-predominant IBS patients and healthy
controls were confirmed, but the carriage of Blastocystis did not significantly alter the faecal microbiota. If Blastocystis-
positive patients represent a separate clinical subtype of IBS, this group is not identified by changes in the microbiota.
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Abbreviations: DNA, Deoxyribonucleic acid; HC, Healthy control subjects; HC-N, Healthy control subjects negative for
Blastocystis carriage; HC-P, Healthy control subjects positive for Blastocystis carriage; IBS, Irritable bowel syndrome;
IBS-C, Constipation-predominant IBS; IBS-D, Diarrhoea-predominant IBS; IBS-M, Mixed bowel habit IBS; IBS-N, Irritable
bowel syndrome patients negative for Blastocystis carriage; IBS-P, Irritable bowel syndrome patients positive for Blastocystis
carriage; PCoA, Principal Coordinates Analysis; PCR, Polymerase chain reaction; rRNA, Ribosomal ribonucleic acid;
XIVC, Xenic in vitro cultureBackground
Human newborn gut contains few organisms at birth [1]
but within hours is colonised by organisms originating from
the mother, diet and environment. Over 90 % of the faecal
mass is microbial, the “faecal microbiota” comprises bac-
teria (93 %), viruses (5.8 %), archaea (0.8 %) and eukaryotes
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attention given to the bacterial component in the literature.
Of the estimated 63–84 bacterial phyla described to date in
humans [3], around 15 are represented in the gastroin-
testinal tract. Ninety percent of the colonic microbiota
consists of two dominant phyla, namely Firmicutes and
Bacteroidetes, with great individual variability seen at spe-
cies and strain level.
The adult faecal microbiota has great inter-individual
variability but is relatively stable over time in individuals
[4]. Factors that influence the human faecal microbiota
include mode of delivery, feeding patterns in earlyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Nagel et al. Microbiome  (2016) 4:47 Page 2 of 9infancy and long-term dietary choices, immunisation,
antibiotic usage, sanitation [5] and gender [6].
Although eukaryotes comprise less than 1 % of the total
faecal microbiota, compositional analysis has identified 37
eukaryotic species in the faeces of healthy adults, including
Blastocystis spp., 18 plant species and 18 fungal species [7].
A recent study of 105 healthy adults showed the prevalence
of Blastocystis carriage to be as high as 56 %, with diverse
subtypes and with stable carriage seen over a duration of
6–10 years in ten subjects [8], suggesting Blastocystis car-
riage may be one of the components of a healthy faecal
microbiota.
Blastocystis spp., first described 100 years ago, are com-
mon, anaerobic, unicellular enteric protozoa found in al-
most all species of animal worldwide. The organism is
found in the lumen of the terminal ileum and caecum of
humans, is non-invasive and requires the presence of fae-
cal bacterial flora for optimum growth [9]. The life cycle is
still unknown although indirect and direct faecal-oral
transmission likely occurs via robust cysts.
Irritable bowel syndrome (IBS) is a chronic heteroge-
neous condition affecting approximately 10 % of the
population worldwide [10]. The disease is characterised by
a clinical symptom complex and classified according to
the predominant bowel habit, namely diarrhoea, constipa-
tion or “mixed” diarrhoea/constipation (IBS-D, IBS-C,
IBS-M) [11].
Blastocystis spp. are reportedly 2.3 times more likely
to be found in the stools of patients with IBS [12] and
three times more likely in diarrhoea-predominant IBS
patients [13] compared to healthy controls. These find-
ings make this parasite of particular interest when in-
vestigating the faecal microbiota of patients with IBS.
Although some reports link certain Blastocystis sub-
types with increased virulence [14], no definite associ-
ation has been established.
The faecal microbiota is altered in IBS and character-
istically displays decreased diversity of organisms, tem-
poral instability and changes in the phyla, particularly
an increased Firmicutes to Bacteroidetes ratio [15].
Changes in the relative abundance of many other bac-
terial families/species in IBS are also reported [16–20].
The discordance between reported changes may be re-
lated to the particular clinical subtype of IBS or other
confounding factors such as diet [21].
A previous study has suggested that irritable bowel sub-
types may be characterised by their faecal microbiota pro-
file and that these subtypes do not necessarily correspond
to their clinical categorisation [20, 22]. We hypothesised
that Blastocystis spp. are one cause of IBS, but as the indi-
vidual parasites are not intrinsically pathogenic, they may
produce symptoms by influencing the faecal microbiota.
In this study, we compared the faecal microbiota in
diarrhoea-predominant IBS patients, positive and negativefor Blastocystis with healthy controls, positive and nega-
tive for Blastocystis carriage.
Methods
Study outline
Forty patients presenting with IBS-D to the Toowoomba
Gastroenterology Clinic and 57 healthy volunteers (healthy
control subjects (HC)) enrolled. Single baseline faecal sam-
ples were collected from all subjects and tested for the
carriage of Blastocystis. The faeces were frozen at −20 °C
within 4 h of collection. Extracted deoxyribonucleic acid
(DNA) was stored for 6–36 months at −20 °C before being
subjected to analysis for the presence/subtype of Blastocys-
tis and faecal microbiota compositional analysis. Compara-
tive analysis was made between subjects with IBS and HC
and between Blastocystis-positive and Blastocystis-negative
IBS (IBS-P, IBS-N) and HC (HC-P, HC-N) subjects.
Inclusion protocol
Patients presenting to the clinic with chronic diarrhoea
from 1 August 2011 to 20 February 2014 were assessed
[23], including a medical consultation and examination,
blood tests (full blood count, electrolytes, thyroid function
tests, celiac antibodies), stool microscopy and culture and
upper and lower endoscopy with duodenal biopsy for hist-
ology and disaccharidase estimation, gastric biopsy and
random ileal and colonic biopsies. Forty eligible symptom-
atic patients, who had no other cause for symptoms iden-
tified and who fulfilled the Rome criteria for diarrhoea-
predominant IBS [11], were enrolled in the study. Healthy
volunteers were recruited from the University of Queens-
land and from asymptomatic members of households con-
taining a symptomatic Blastocystis-positive patient. HC
individuals were enrolled if they were in general good
health with no current gastrointestinal symptoms; no past
medical or medication history was taken. All patients who
were invited to participate consented to enrolment and
completed the study. No record was taken in any subject
of diet, pre- or pro-biotic intake.
Exclusion protocol
Non-pregnant subjects between 15 and 75 years of age
were recruited for the study. Patients with significant
systemic diseases or co-morbidities were excluded.
Subjects were excluded if they had had a course of any




All samples were run in parallel for the presence of Blas-
tocystis spp. using an unstained wet faecal smear and
xenic in vitro culture (XIVC).
Table 1 Characteristics of clinical subgroups
IBS-P IBS-N HC-P HC-N
(n = 26) (n = 13) (n = 42) (n = 13)
Age
(mean ± sd) 45.6 ± 13.6 45.8 ± 14.0 41.8 ± 15.6 41.2 ± 13.4
Female (n, %) 20 (76.9) 10 (76.9) 15 (38.5) 9 (69.2)
Blastocystis subtypes
(n, %)
ST1 5 (19.2) 12 (28.6)
ST3 8 (30.8) 12 (28.6)
ST4 7 (26.9) 6 (14.3)
Other subtypes
(including ST2,5–8)
6 (23.1) 7 (28.6)
Medications (n, %)
Subjects on PPI/H2Bl 7 (27 %) 4 (29 %)
Nil or OCP only 14 (54 %) 4 (29 %)
IBS-P patients with irritable bowel syndrome positive for Blastocystis, IBS-N
patients with irritable bowel syndrome negative for Blastocystis, HC-P healthy
controls positive for Blastocystis, HC-N healthy controls negative for Blastocystis,
PPI proton pump inhibitor therapy, H2Bl histamine 2 blocker therapy, OCP oral
contraceptive pill
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QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany)
according to Nagel et al. [23]. The genomic DNA from
stool and faecal cultures from all subjects were sub-
jected to polymerase chain reaction (PCR) analyses to
test for the presence of Blastocystis [23] using theTable 2 Mean relative abundance of bacterial phyla seen in clinical
Phyla Total IBS IBS-P
















aSignificant difference in total IBS cf total HC using Mann-Whitney test
IBS-P patients with irritable bowel syndrome positive for Blastocystis, IBS-N patients
positive for Blastocystis, HC-N healthy controls negative for Blastocystis, cf comparenested Wong protocol [24]. All positive PCR products
were subjected to DNA sequencing and phylogenetic
analysis to identify the particular ST [23]. A patient was
considered to be positive for Blastocystis if any one of
the tests was positive.
Compositional analysis of faecal DNA using 16S rRNA genes
The primer sequences and protocol was based on
Caporaso et al. [24], with local modifications. Faecal
DNA was extracted as described above and quantified
using a Qubit fluorometer, and 1-ng samples were amp-
lified using the 16S ribosomal ribonucleic acid (rRNA)
gene V4/5 primers (515F: GTGCCAGCMGCCGCGG-
TAA and 806R: GGACTACHVGGGTWTCTAAT)
(Additional file 1). Specifically, we used a mixture of
gene-specific primers and gene-specific primers tagged
with ion torrent-specific sequencing adaptors and bar-
codes. The tagged and untagged primers were mixed at
a ratio of 90:10. Using this method, the approximately
10 cycle inhibition observed by using long tagged primers
could be reversed, and hence, we achieved amplification
of all samples using 18–20 cycles, thus minimising
primer-dimer formation and allowing streamlined down-
stream purification. Amplification was confirmed by agar-
ose gel electrophoresis, and product formation was
quantified by fluorometry. Up to 100 amplicons were
diluted to equal concentrations and adjusted to a final
concentration of 15 pM. Templated Ion Shere Particles
(ISP) were generated on an Ion One Touch 2 (Lifesubgroups (%)
IBS-N Total HC HC-P HC-N
(n = 13) (n = 55) (n = 42) (n = 13)
5.145 2.450 0.668 4.600
25.515 47.700 48.467 45.222
0.006 0.023 0.025 0.015
0 0.001 0.0005 0.003
60.735 41.431 41.970 39.686
0.775 0.084 0.110 0
0.011 0.018 0.020 0.012
1.858 3.297 3.481 2.700
5.029 5.417 4.758 7.545
0 0.001 0.002 0
0.012 0.003 0.003 0.005
0 0.0004 0.0005 0
0 0.004 0.005 0
0.515 0.308 0.347 0.183
0 0 0 0
with irritable bowel syndrome negative for Blastocystis, HC-P healthy controls
Table 3 Firmicutes to Bacteroidetes ratio in clinical subgroups (abundance of Firmicutes/abundance of Bacteroidetes)
Total IBS IBS-P IBS-N Total HC HC-P HC-N
Firmicutes/Bacteroidetes ratio (mean ± standard deviation) 7.13 ± 13.40a 6.19 ± 14.85 9.00 ± 10.16 2.28 ± 7.19 1.42 ± 1.179 5.08 ± 14.51
aSignificant difference in total IBS cf total HC using Mann-Whitney test
IBS-P patients with irritable bowel syndrome positive for Blastocystis, IBS-N patients with irritable bowel syndrome negative for Blastocystis, HC-P healthy controls
positive for Blastocystis, HC-N healthy controls negative for Blastocystis, cf compare
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on a PGM (LifeTechnologies) for 800 cycles using
400 bp sequencing kit yielding a modal read length of
309 bp. Reads were trimmed for quality purposes using
TorrentSuite 4.0.2 [24]. This method has been tested
on commercial mock community DNA samples and
shows good concordance with expected results (data
not shown).
Analysis of 16S rRNA gene sequences
Metataxonomic analysis using culture-independent high
throughput 16SSU rRNA quantitative gene sequencing
and microarrays was performed on the PCR-derived
sequences. The data was analysed using software analysis
programme Quantitative Insights into Microbial EcologyTable 4 Comparison of bacterial profiles in subjects with and witho
Phylum (L2) Class (L3) Order (L4)
Euryarchaeota Methanobacteria ↑ Methanobacteriales ↑
Actinobacteria Actinobacteria Actinomycetales ↑
Bifidobacteriales
Coriobacteriales
Bacteroidetes ↓ Bacteroidia ↓ Bacteroidales ↓
Firmicutes Bacilli Lactobacillales
Clostridia ↑ Clostridiales ↑
Erysipelotricha Erysipelotrichales
Negativicutes ↓ Selenomonadales ↓
Proteobacteria Alphaproteobacteria ↑ Rhizobiales ↑
(Unclassified) ↑ Other ↑ Other ↑
Bold entries indicate significant difference between groups (p < 0.05). ↑ and ↓ indic
subjects, respectively
L level(QIIME, version 1.7) [24]. The following commands were
applied to the derived 16S rRNA gene sequences [25]: (i)
the rRNA gene sequence FASTq reads were separated into
two separate libraries, one containing “sequences (FASTA
files)” and the other “quality of DNA information
(QUAL)” scores; (ii) each file in the sequence library was
assigned a unique subject identity barcode, creating a
“mapping” library; (iii) PCR “mixed sequence” chimaeras
were removed using a reference file and identification of
“de novo” chimeric sequences; (iv) operational taxonomic
units based on 97 % specific16S rRNA gene sequence
identities were used to distinguish different species of mi-
crobes, and these were grouped into their most likely
phylum/class/order/family/genus using GreenGenes data-
base, Version 12_10) [26]. Genomic analysis was obtainedut IBS
Family (L5) Genus (L6)
Methanobacteriaceae ↑ Methanobrevibacter ↑








Streptococcaceae ↑ Streptococcus ↑
Lachnospiraceae ↑ Anaerostipes ↑
Blautia ↑
Lachnospiracea_incertae_sedis ↑




Veillonellaceae ↓ Allisonella ↓
Dialister ↓
Hyphomicrobiaceae ↑ Gemmiger ↑
Other ↑ Other ↑
ate significant (p < 0.05) increase or decrease in IBS relative to healthy
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cies subtype identification [24]. For diversity analyses, all
samples were rarefied to 5000 reads per sample, and
hence, all presented analyses are relative comparisons.
Alpha and beta-diversity analyses were performed on the
samples, and the latter was used to create Principal Coor-
dinates Analysis (PCoA) graphs.Statistical analysis
Statistical analysis was carried out using IBM SPSS
Statistics (IBM SPSS Statistics for Windows, Version
22.0. Armonk, NY: IBM Corp).
Percentages (relative abundance) of gut microbiota
at phylum and genus level across the four clinical
groups were analysed using Kruskal-Wallis test. Those
species with a significant overall difference wereTable 5 Comparison of relative abundance of selected (selection ba
determined by Kruskal-Wallis test with p < 0.05) bacterial species acr
Species Mean ± SD (%)
IBS-P
(n = 26)
Actinomyces spp.a 0.019 ± 0.052
Anaerostipes spp.ba 0.248 ± 0.498
Papillibacter spp. 0
Blautia spp.ba 1.130 ± 1.923
Lauconostoc spp.ac 0.035 ± 0.058
Eggerthella spp.a 0.018 ± 0.058
Weissella spp. 0.038 ± 0.066
Bifidobacterium spp.ba 2.440 ± 8.130
Allisonella spp. 0.008 ± 0.028
Bifidobacteriaceae, Other spp. 0.038 ± 0.156
Streptococcus spp.a 1.276 ± 2.612
Lachnospiracea_incertae_sedis spp.a 2.092 ± 3.592
p_Bacteria, Other spp.bd 4.893 ± 5.681
Clostridium XI spp.a 0.224 ± 0.378
Eubacterium spp. 0.004 ± 0.013
Acinetobacter spp. 0.017 ± 0.036
Dialister spp.a 0.227 ± 0.727
Gordonibacter spp. 0.005 ± 0.012
Canternibacter spp. 0.004 ± 0.016
Oxalobacteraceae, Other spp. 0.049 ± 0.080
Olsenella spp. 0
Alistipes spp.b 6.142 ± 5.326
Clostridium IV spp.c 0.829 ± 1.501
aSignificant post hoc difference IBS-N vs HC-P
bSignificant post hoc difference IBS-P vs IBS-N
cSignificant post hoc difference HC-P vs HC-N
dSignificant post hoc difference IBS-P vs HC-Nfurther analysed for between group differences using
the following equation [27]:
RBari‐RBarjj > ZSqrt N N þ 1ð Þ=12ð Þ 1=niþ 1=njð Þ½ 
where RBari, RBarj, ni and nj are the mean of the
ranks and the sample sizes associated with the ith
and jth groups. N is the total sample size, and Z is
the critical value from the standard normal curve (Z
= 2.638 for k = 4 groups and where alpha = 0.05/(k*(k
− 1)) = 0.0083333). Statistical significance of multiple
comparisons was adjusted using Bonferroni
correction.sed on overall statistical significance across all clinical groups,
oss the four clinical subgroups
IBS-N HC-P HC-N
(n = 13) (n = 42) (n = 13)
0.035 ± 0.043 0.001 ± 0.005 0.015 ± 0.023
2.040 ± 2.235 0.123 ± 0.157 0.395 ± 0.793
0.025 ± 0.067 0 0
6.505 ± 5.909 0.450 ± 0.366 1.975 ± 4.392
0.002 ± 0.006 0.063 ± 0.101 0.005 ± 0.012
0.112 ± 0.189 0.003 ± 0.010 0.008 ± 0.015
0.003 ± 0.011 0.090 ± 0.172 0.002 ± 0.006
3.915 ± 5.362 0.408 ± 1.039 4.195 ± 9.828
0 0.016 ± 0.049 0.149 ± 0.443
0.025 ± 0.032 0.003 ± 0.013 0.085 ± 0.254
0.643 ± 0.657 0.192 ± 0.273 0.595 ± 1.476
2.600 ± 1.666 0.813 ± 0.769 1.206 ± 1.048
1.858 ± 2.906 3.481 ± 3.747 2.700 ± 6.159
0.911 ± 0.761 0.255 ± 0.505 0.312 ± 0.511
0.046 ± 0.105 0.004 ± 0.013 0.015 ± 0.038
0.002 ± 0.006 0.031 ± 0.106 0
1.997 ± 4.464 3.799 ± 11.633 4.292 ± 6.127
0.012 ± 0.029 0 0.002 ± 0.006
0 0.154 ± 0.546 0.046 ± 0.126
0.006 ± 0.017 0.050 ± 0.095 0.022 ± 0.072
0 0.006 ± 0.023 0
1.975 ± 2.507 5.473 ± 5.802 4.992 ± 5.512
0.495 ± 0.438 1.037 ± 1.373 0.277 ± 0.400
Nagel et al. Microbiome  (2016) 4:47 Page 6 of 9Results
Subjects
Table 1 shows the age, gender, medication history,
Blastocystis status and subtype of all subjects (Table 1).
A female predominance was found in the IBS group
(λ2 = 15.25, p < 0.05).
Bacterial phyla seen in the study subjects
Metataxonomic analysis was performed on 97 subjects
(Additional file 1). The two bacterial phyla with the
highest relative abundance were Firmicutes and Bac-
teroidetes (46.27 and 40.99 %, respectively) (Table 2).
Between-gender differences of relative abundance were
found in some bacterial species at the genus level
(Additional file 2: Table S1), but none at the phylum
level (all p > 0.05).
Comparison of bacterial profiles in subjects with and
without IBS
Bacteroidetes relative abundance was significantly reduced
in the IBS group, and the Firmicutes to Bacteroidetes ratio
was three times higher in the IBS group compared to the
HC (Tables 2 and 3) (p = 0.02).
A number of genera of microbes showed differences
in relative abundance between IBS and HC subjects,
and many of these differences reached statistical signifi-
cance (Table 4).
Comparison of bacterial profiles across the four clinical
subgroups
No significant differences were found between major bac-
terial phyla profiles in IBS-P and IBS-N patients (Table 2).
The minor phyla only have small numbers of subjects in
each group making meaningful statistical interpretation
difficult.Fig. 1 Title: Principal Co-ordinates Analysis graph of Blastocystis carriage s
dots Blastocystis-negativeSignificant differences in bacterial profiles at genus
level were not found between the clinical subgroups,
particularly between IBS-P and IBS-N groups (Table 5).
Figure 1 (stratified for Blastocystis carriage), Fig. 2a
(unweighted, recording presence but not accounting
for abundance of different phyla and species) and
Fig. 2b (weighted for differences in abundance of phyla
and species) illustrate the similarities of the bacterial
profile amongst the four clinical groups, with consid-
erable overlap, and no single group found to be an
outlier.
Discussion
Previously reported changes in the faecal microbiota of
the two dominant phyla, with a raised Firmicutes to
Bacteroides ratio in IBS patients compared to HC,
were confirmed in this study comprising diarrhoea-
predominant IBS patients. Reductions in relative abun-
dance in our study of diarrhoea-predominant patients
were in accord with Parabacteroides spp., but results
found in our study for Actinomyces, Bifidobacteria-
cea_Other, Dialister,Veillonellaceae and Methanobrevi-
bacter spp. differed from previous results reported for
constipation-predominant IBS [16].
Many studies of the faecal microbiota in IBS patients
have not separated out clinical subtypes of IBS (diarrhoea,
constipation, or mixed-predominant) or other confound-
ing factors [19], and this may account for differences in
results. In our study, almost half the IBS patients were tak-
ing either no medication or only the oral contraceptive pill
(OCP) and numbers of patients on medication were high
in both IBS-P and IBS-N groups. Universally, IBS has a fe-
male predominance [10]. Sex hormone modulation of the
gut microbiota has been reported [28], and it is likely
OCP therapy has some impact on the faecal microbiota.
Nevertheless, this study did not identify any changes intatus (unweighted). Legend: Blue dots Blastocystis-positive, red
Fig. 2 a Title: Principal Co-ordinates Analysis graph of all clinical subgroups (unweighted). Legend: IBS-P red squares, IBS-N blue triangles, HC-P
yellow circles, HC-N green triangles. b Title: Principal Coordinates Analysis graph of all clinical subgroups (weighted). Legend: IBS-P red squares,
IBS-N blue triangles, HC-P yellow circles, HC-N green triangles
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genus) associated with gender (Additional file 3). Approxi-
mately one third of subjects with IBS were taking acid
suppression therapy that has been reported to change the
gastric microbiota significantly but have much less effect
on the colonic microbiota [29].
In our study of diarrhoea-predominant IBS pa-
tients, no significant differences between the IBS-
P, IBS-N, HC-P and HC-N groups were seen at the
phyla or genus level. Although IBS patients have a
different faecal microbiota profile compared to
healthy subjects, the carriage of Blastocystis does
not make a significant difference to this profile.
This suggests that if Blastocystis spp. do cause
some cases of IBS, mechanisms other thanalteration of the faecal microbiota must be in-
volved. It is possible that some Blastocystis organ-
isms have unique, as yet undefined, pathological
attributes [30] or that the host immune response
may be an important factor in determining clinical
response to Blastocystis infection [31].Conclusions
Changes in the faecal microbiota in the dominant phyla
and the Firmicutes to Bacteroidetes ratio are confirmed in
diarrhoea-predominant IBS patients compared to HC sub-
jects. Although IBS patients with Blastocystis may consti-
tute a separate clinical IBS group, this group is not
characterised by changes in the faecal microbiota.
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